BioNTech

BioNTech Charts Aggressive Oncology Path, Backed by Strong Cash Reserves

Brett Shapiro - April 17, 2026

BioNTech’s Billion-Euro Oncology Bet Nears Key Regulatory Juncture

angelina - April 14, 2026

BioNTech Faces Mounting Challenges as Key Trials and Leadership Changes Weigh on Sentiment

April 8, 2026

BioNTech战略转型：千亿储备护航，管理层寻求更大资本运作空间

kashif hafeez - April 7, 2026

BioNTech’s Clinical Trial Halt Casts Shadow Over Future Revenue Streams

angelina - April 6, 2026

BioNTech战略转型：后疫情时代的破局之路

kashif hafeez - April 5, 2026

百欧恩泰的战略转型：千亿储备押注肿瘤治疗新时代

April 4, 2026

BioNTech’s Strategic Pivot Amid Regulatory and Revenue Challenges

Brett Shapiro - April 3, 2026

BioNTech疫苗审批遇阻，肿瘤管线成转型关键

angelina - April 3, 2026

BioNTech股价逆势上扬：新冠疫苗试验意外终止背后的逻辑

angelina - April 2, 2026

BioNTech Shifts Strategic Focus as COVID Vaccine Trial Concludes

kashif hafeez - April 2, 2026

BioNTech’s Strategic Pivot Gains Traction with Promising Clinical Data

kashif hafeez - April 1, 2026

BioNTech转型阵痛：研发管线扩张难掩市场疑虑

April 1, 2026

BioNTech’s Oncology Ambitions Bolstered by Promising Lung Cancer Trial Data

March 31, 2026

BioNTech肿瘤管线进展引关注：肺癌治疗数据成焦点

angelina - March 29, 2026

1 234...9 Page 3 of 9